Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

A biomaterials roadmap from retinoic acid biology to kidney regenerative therapy.

Created on 02 Oct 2026

Authors

Ru-Yu Tan, Li-Li Huang, Qin-Ying She, Yun-Ci Ma, Min-Hong Liu, Li-Juan Li, Chao Zhang, Yi-Wen Zhong, Shan Zhou, Hui-Xin Bi

Published in

iScience. Volume 29. Issue 10. Pages 117554. Oct 16, 2026. Epub Sep 18, 2026.

Abstract

The mammalian kidney cannot generate new nephrons after birth, a key driver of chronic kidney disease progression toward end-stage renal disease. Retinoic acid (RA) is an evolutionarily conserved morphogen essential for kidney development, and its signaling is reactivated after injury to coordinate repair-yet this endogenous repair program is transient and insufficient to guide the kidney along the regenerative continuum toward de novo nephron formation. Despite its regenerative potential, RA's clinical translation is limited by systemic toxicity, a narrow therapeutic window, and poor pharmacokinetics. Here, we synthesize evidence from developmental biology and injury models showing that RA can activate endogenous renal progenitor programs. We then analyze its pharmacological and toxicity barriers and introduce a developmental bioinspiration framework using renal-targeted nanocarriers and multifunctional scaffolds to overcome these obstacles. By recapitulating native RA signaling dynamics, these platforms aim to steer the adult kidney away from maladaptive fibrosis and toward functional restoration.

PMID:
42823964
Bibliographic data and abstract were imported from PubMed on 02 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 9
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement